SCHEMBL2721702

SCHEMBL2721702

O=C(O)c1c2ccc(Br)cc2nn1-c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.54
AURKA O14965 1/20 0.54
CSNK1A1 P48729 1/20 0.54
CDK8 P49336 1/20 0.54
NEK2 P51955 1/20 0.54
LIMK1 P53667 1/20 0.54
CDK5 Q00535 1/20 0.54
DYRK1A Q13627 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
KMT2A Q03164 5/20 0.42
MEN1 O00255 2/20 0.42
LMNA P02545 2/20 0.41
SLC2A1 P11166 1/20 0.41
SLC2A3 P11169 1/20 0.41
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
PPP1CA P62136 1/20 0.38
PPARA Q07869 1/20 0.36
GRM5 P41594 1/20 0.35
PTGFR P43088 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108907 0.88 CDK5 (0.44) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL9910899 0.87 CHEK1 (0.70) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL9107560 0.85 SLC2A1 (0.46) SLC2A1SLC2A3
SCHEMBL15940565 0.81 CHEK1 (0.51) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL9108281 0.77 ESR2 (0.44) KMT2AMEN1LMNASLC2A1SLC2A3
SCHEMBL2720819 0.77 CHEK1 (0.42) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL9910900 0.77 CHEK1 (0.59) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL2723737 0.74 MEN1 (0.38) KMT2AMEN1LMNASLC2A1SLC2A3
SCHEMBL4730929 0.74 CDK5 (0.41) CHEK1AURKACSNK1A1CDK8NEK2
SCHEMBL4940862 0.72 CHEK1 (0.44) CHEK1AURKACSNK1A1CDK8NEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546389-B2 Viral polymerase inhibitors BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-10-01 US disclosed
US-8546389-B2 Viral polymerase inhibitors BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-10-01 US disclosed
US-8546389-B2 Viral polymerase inhibitors BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-10-01 US disclosed
EP-2630128-A1 VIRAL POLYMERASE INHIBITORS Biota Scientific Management Pty Ltd (AU) 2013-08-28 EP disclosed
US-20120142686-A1 VIRAL POLYMERASE INHIBITORS BIOTA SCIENTIFIC MANAGEMENT PTY LTD 2012-06-07 US disclosed
US-20120142686-A1 VIRAL POLYMERASE INHIBITORS BIOTA SCIENTIFIC MANAGEMENT PTY LTD 2012-06-07 US disclosed
US-20120142686-A1 VIRAL POLYMERASE INHIBITORS BIOTA SCIENTIFIC MANAGEMENT PTY LTD 2012-06-07 US disclosed
WO-2012051659-A1 VIRAL POLYMERASE INHIBITORS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-04-26 WO disclosed
WO-2012051659-A1 VIRAL POLYMERASE INHIBITORS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142686-A1 VIRAL POLYMERASE INHIBITORS POLR2E, POLM, POLR2H CHEK1 3433/4885AURKA 2705/4885CSNK1A1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.